Clinical trials: Chest--Diseases
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer.
- Trial name
- NCT00415363
- Testing
- enzastaurin
- Where
- 7 sites in Denmark, Norway and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Non-small-cell Lung Cancer
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
The purpose of this study is to evaluate the overall response rate and disease free survival for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.
- Trial name
- NCT01843647
- Testing
- Icotinib, Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Non Small Cell Lung Cancer
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy…
- Trial name
- NCT03574649
- Testing
- Nab-paclitaxel, Cisplatin, 5Fluorouracil
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Non-small-cell Lung Cancer
A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer
This is a Phase I-II study designed to investigate nimotuzumab (TheraCIM h-R3) in combination with external radiation in patients with non-small cell lung cancer.
- Trial name
- NCT00369447
- Testing
- External radiotherapy, nimotuzumab
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- YM BioSciences
Non-small Cell Lung Cancer
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic…
- Trial name
- NCT04656652
- Testing
- DS-1062a, Docetaxel
- Where
- 209 sites in United States, Argentina and 24 more
- Volunteers
- 605 people
- Sponsor
- Daiichi Sankyo
Chemotherapy-induced Febrile Neutropenia
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
This is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy.
- Trial name
- NCT01813721
- Where
- 90 sites in Australia, Austria and 9 more
- Volunteers
- 1,007 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients
Lung cancer is among the most common cancers in the world and its incidence continues to increase. Chemotherapy for patients with Non-Small Cell Lung Cancer (NSCLC) has been under investigation for several decades and several new…
- Trial name
- NCT00044538
- Testing
- BAY59-8862 (Cytotoxic Taxane)
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 102 people
- Sponsor
- Bayer
Non-small Cell Lung Cancer
Test-retest Evaluation of [18F]F-AraG PET
This pilot study aims to evaluate the test-retest variability of [18F]F-AraG-PET imaging in patients with advanced NSCLC tumors.
- Trial name
- NCT06084806
- Testing
- [18F]F-ARAG PET
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- CellSight Technologies, Inc.
Non-Small Cell Lung Cancer
PD-L1 Expression in Lung Cancer
This study will measure PD-L1 expression in metastatic NSCLC (primary tumour and metastatic lesions) using [99mTc]-NM-01 SPECT/CT and compare to PD-L1 percentage expression determined by immunohistochemistry (IHC).
- Trial name
- PELICAN (NCT04992715)
- Testing
- [99mTc]-NM01 SPECT/CT
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- NanoMab Technology (UK) Limited
Neoplasms
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited…
- Trial name
- GARNET (NCT02715284)
- Testing
- Dostarlimab
- Where
- 128 sites in United States, Argentina and 11 more
- Volunteers
- 729 people
- Sponsor
- Tesaro, Inc.
Small-cell Lung Cancer
The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.
- Trial name
- NCT04691063
- Testing
- SHR-1316; Carboplatin; Etoposide；Radiotherapy, Palcebo; Carboplatin; Etoposide；Radiotherapy
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chest Wall Disorder, Neuromuscular Disease
AutoVPAP Versus VPAP; Assessment of Sleep and Ventilation
The aim of the study is to compare the effects of a modified form (AutoVPAP) of the VPAP non-invasive ventilator versus standard VPAP ventilation on sleep quality and breathing during sleep in stable patients with nocturnal…
- Trial name
- NCT00252252
- Testing
- VPAP non-invasive ventilator, AutoVPAP non-invasive ventilator
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- ResMed
Neoplasms, Neoplasms, Glandular and Epithelial
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02897778
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Carcinoma, Non-Small-Cell Lung
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
To provide expanded access and to evaluate the safety, tolerability and efficacy of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR)…
- Trial name
- NCT01931306
- Testing
- Afatinib
- Where
- 8 sites in South Korea
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic…
- Trial name
- KEYNOTE-799 (NCT03631784)
- Testing
- Pembrolizumab 200 mg, Paclitaxel 45 mg/m^2, Carboplatin AUC6
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC Stage IV
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1)…
- Trial name
- NCT06745908
- Testing
- N-803, Tislelizumab, Docetaxel
- Where
- 49 sites in United States, Canada and 1 more
- Volunteers
- 507 people
- Sponsor
- ImmunityBio, Inc.
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-V (NCT02389946)
- Testing
- Orsiro DES, Xience DES
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Biotronik, Inc.
Coronary Disease, Heart Diseases
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- BIOMAG-III (NCT07258290)
- Testing
- Freesolve RMS, Xience DES
- Where
- 3 sites in United States, Latvia
- Volunteers
- 1,859 people
- Sponsor
- Teleflex
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.